Tatiana J. Carneiro's academic career is based in the Biochemistry field. She concluded the BSc degree in 2015 and the MSc degree in Biomolecular Methods in 2017, both at University of Aveiro, with scientific work developed within the scope of metabolomics. In 2018, she worked as a research fellow on the BioIMPACT project (Ref. PTDC/QEQ-MED/1890/2014, funded by FCT), which aimed to evaluate the metabolic impact of new-synthetized complex Palladium(II)-spermine as a potential antineoplastic agent with reduced side-effects compared to the conventional drug cisplatin. From 2019 to 2024, she pursued a PhD in Biochemistry at the University of Aveiro, focusing on identifying biomarkers of the in vitro and in vivo metabolic impact of metal-based drugs, as potential new low-toxic therapeutic agents against triple-negative breast cancer. The work developed during her PhD led to fifteen publications in peer-reviewed journals, with Tatiana J. Carneiro as the first author in nine papers, as well as participation in national and international conferences with fifteen posters and oral presentations. Currently, she is a postdoctoral fellow in the Body Barrier Immunometabolism Laboratory, at UC-Biotech (CIBB/CNC, University of Coimbra). She is involved in the Kinder-GUT project (Ref. HR22-00754, funded by the “La Caixa” Foundation - CaixaResearch Health 2022), which aims to identify new therapeutic targets for gastrointestinal infections by characterizing the molecular patterns of intestinal intraepithelial lymphocytes in the contexts of both intestinal absorption/metabolism and immune response to pathogens.